Robert Toto, MD: With regard to health care resource utilization in the CKD [chronic kidney disease] population, there was a recent poster looking at translating the findings from the DAPA-CKD study, ...

An overview of the implications of the recent dapagliflozin data in chronic kidney disease (CKD) treatment to US clinicians and payers. Robert Toto, MD: The implication for clinicians is that ...

A recent analysis indicates that dapagliflozin is a cost-effective treatment in patients with chronic kidney disease in addition to standard of care. Washington, DC (November 2, 2022) — The burden of ...

AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy of the drug, at the ...

Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 ...